CMS Sets Code for Eagle Pharma BELRAPZO

Eagle’s bendamustine 500mL hydrochloride injectable will be sold as BELRAPZO beginning June 3, 2019

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq:EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code, or J-code (J9036), for BELRAPZO™ (bendamustine 500mL hydrochloride injection). The J-code will become effective on July 1, 2019. Eagle’s bendamustine 500mL hydrochloride injectable will be sold as BELRAPZO beginning June 3, 2019. “We launched our 500mL bendamustine hydrochloride injection, to address the need in the market for our unique formulation at a lower price point. The new J-code provides reimbursement coding clarity to outpatient facilities and physicians that will administer BELRAPZO, facilitating access for patients, and Medicare, Medicaid and commercial insurance reimbursement,” said Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals. About BELRAPZO Indications BELRAPZO is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. BELRAPZO is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

https://www.marketscreener.com/EAGLE-PHARMACEUTICALS-INC-15758349/news/Eagle-Pharmaceuticals-CMS-Establishes-Unique-J-Code-for-BELRAPZO-trade-Bendamustine-500mL-Hydroc-28458283/